Market Overview

GenMark Bulls Emboldened By Accelerated ePlex Panel Clearance

Share:
GenMark Bulls Emboldened By Accelerated ePlex Panel Clearance
Related GNMK
The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial
65 Biggest Movers From Yesterday

GenMark Diagnostics, Inc (NASDAQ: GNMK) surged 12 percent Wednesday after announcing FDA market clearance for its ePlex Blood Culture Identification Fungal Pathogen Panel. The news bolstered Raymond James' bullish thesis for the stock. 

The Analyst

Raymond James analyst John Hsu maintained a Market Outperform rating on GenMark with a $7 price target.

The Thesis

The second of three ePlex panels was set to cover more fungal pathogens than any competing product. GenMark boosted the candidate’s appeal by achieving clearance sooner than Raymond James had expected, Hsu said in a Wednesday note. 

“Importantly, with today's FDA clearance, we see the regulatory hurdles as further derisked and supportive of our positive thesis in a 31-percent revenue CAGR through 2020, driven by continued ePlex platform utilization and menu expansion,” the analyst said. 

Looking ahead, Raymond James anticipates a 10-percent year-over-year increase in annuity per placement. Additionally, because the testing is inpatient, the analyst considers it insulated from insurance decisions that affect outpatient reimbursement.

GenMark awaits clearance of its gram negative panel to seize a $500-million total addressable market for sepsis prevention, and altogether, the panel trio will detect pathogens that cause more than 95 percent of bloodstream infections, according to Raymond James. 

Until then, the fungus panel on its own is seen to meet a high demand as fungal pathogens increase as a cause of blood infections.

Price Action

GenMark shares were down 2.51 percent at $4.28 at the time of publication Thursday. 

Related Links:

6 Valuable Pipeline Drugs With Upcoming Catalysts

Stemline's Elzonris Launch On Schedule, HC Wainwright Says In Bullish Initiation

Latest Ratings for GNMK

DateFirmActionFromTo
Oct 2018Canaccord GenuityMaintainsBuyBuy
Jul 2018Canaccord GenuityMaintainsBuyBuy
Jun 2018Canaccord GenuityMaintainsBuyBuy

View More Analyst Ratings for GNMK
View the Latest Analyst Ratings

Posted-In: John Hsu Lawrence Keusch Raymond JamesAnalyst Color News Reiteration FDA Analyst Ratings Best of Benzinga

 

Related Articles (GNMK)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
CABOKeyBancUpgrades1,025.0
PANWBMO CapitalUpgrades240.0
UAAGoldman SachsUpgrades28.0
FDCBarclaysDowngrades23.0
GPSGoldman SachsDowngrades0.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

GBP/USD Forecast: Holiday-Thinned Trading Will Keep Sterling in 1.2600-1.2700 Range

In The December Bloodbath, These Hidden Factors Might Be Prompting Traders To Buy